Ghrelin News and Research

RSS

Ghrelin is a hormone produced mainly by P/D1 cells lining the fundus of the human stomach and epsilon cells of the pancreas that stimulates appetite. Ghrelin levels increase before meals and decrease after meals. It is considered the counterpart of the hormone leptin, produced by adipose tissue, which induces satiation when present at higher levels. Ghrelin is also produced in the hypothalamic arcuate nucleus where it stimulates the secretion of growth hormone from the anterior pituitary gland.

Ipsen's first-quarter 2010 drug sales up 6.2%

Ipsen reported today its sales for the first quarter 2010.

3 May 2010

Dietary protein for overall health

The importance of high-quality protein foods in overall health was among the topics discussed this week at Experimental Biology 2010 in Anaheim, Calif. Researchers from a variety of institutions discussed studies that looked at varying levels of dietary protein intake to promote health throughout life including the role of protein in weight loss and muscle maintenance.

3 May 2010

Laughter is truly the best medicine says new research

A new study has shown that laughter may be one of the simplest exercises that has similar effects on the body as pumping iron in the gym. Researchers have named “Laughercise” as significant elevators of mood, stress busters, immunity boosters and blood pressure and cholesterol reducers. It can also stimulate appetite for the malnourished.

28 Apr 2010

Laughter increases production of antibodies and activates body's protective cells

Laughter is a highly complex process. Joyous or mirthful laughter is considered a positive stress (eustress) that involves complicated brain activities leading to a positive effect on health. Norman Cousins first suggested the idea that humor and the associated laughter can benefit a person's health in the 1970s. His ground-breaking work, as a layperson diagnosed with an autoimmune disease, documented his use of laughter in treating himself—with medical approval and oversight—into remission.

27 Apr 2010

Eating protein-rich eggs for breakfast reduces hunger, decreases calorie consumption throughout the day

A new study demonstrates that eating protein-rich eggs for breakfast reduces hunger and decreases calorie consumption at lunch and throughout the day. The study, published in the February issue of Nutrition Research, found that men who consumed an egg-based breakfast ate significantly fewer calories when offered an unlimited lunch buffet compared to when they ate a carbohydrate-rich bagel breakfast of equal calories.

7 Apr 2010

Hormone ghrelin may improve appetite in gastric cancer patients

In gastric cancer patients who have had part or all of their stomach removed, the hormone ghrelin may lessen post-operative weight loss and improve appetite, according to a new study in Gastroenterology, the official journal of the American Gastroenterological Association Institute.

1 Apr 2010

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Tranzyme Pharma announced today that data from the Phase 2 clinical trial of ulimorelin (TZP-101) for the treatment of severe gastroparesis have been selected for an oral presentation at Digestive Disease Week (DDW) 2010 being held May 1-5, 2010 in New Orleans, LA.

12 Mar 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Ipsen, a global biotechnology specialty care group, and Rhythm Pharmaceuticals, a biotechnology company developing peptide therapeutics for metabolic diseases, announced today that they have concluded a license agreement for Ipsen’s proprietary peptide therapeutics targeting obesity, metabolic diseases, and gastrointestinal disorders.

12 Mar 2010

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

Spanish researchers determined that rats treated with recombinant ghrelin displayed a reduction in liver fibrosis. Ghrelin, a stomach hormone, reduced the amount of fibrogenic cells by 25% in the treated rodents. Research further showed ghrelin prevented acute liver damage and reduced oxidative stress and inflammation in the animal models.

1 Mar 2010

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

Geneva, situated at the heart of Europe, provides a fitting setting for the 10th Annual Spring Meeting of the European Society of Cardiology Council (ESC) on Cardiovascular Nursing and Allied Professionals (CCNAP), 12 - 13 March 2010, with its special theme: "Uniting to Improve Cardiovascular Practice".

11 Feb 2010

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Tranzyme Pharma today announced that the United States Adopted Name Council (USAN) has approved the generic name “ulimorelin” for Tranzyme’s novel, late-stage, prokinetic agent TZP-101. Ulimorelin, if approved, is expected to be a first-in-class drug for the treatment of gastrointestinal (GI) dysmotility indications in acute care (hospital-based) settings.

27 Jan 2010

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Elixir Pharmaceuticals, Inc. announced today that its partner, Siena Biotech S.p.A., has commenced Phase 1 clinical testing of Elixir’s potent, first-in-class SIRT1 (sirtuin-1) inhibitor for the treatment of Huntington’s Disease.

8 Jan 2010

Hunger hormone can intensify high-fat food consumption

The premise that hunger makes food look more appealing is a widely held belief - just ask those who cruise grocery store aisles on an empty stomach, only to go home with a full basket and an empty wallet.

28 Dec 2009

Hormone ghrelin influences the consumption of alcohol, study shows

A Faculty of 1000 evaluation examines how a stomach-produced hormone that influences the desire to eat and consume alcohol could be switched off to control drinking problems.

23 Dec 2009

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

AEterna Zentaris Inc. (the "Company"), a global biopharmaceutical company focused on oncology and endocrine therapy, today announced the termination of its agreement with sanofi-aventis U.S. ( SNY) dated March 5, 2009 for the development, commercialization and licensing of cetrorelix in benign prostatic hyperplasia (BPH) for the U.S. market, following the Company's announcement last week of the results for its European Phase 3 study for cetrorelix in BPH.

18 Dec 2009

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Tranzyme Pharma today announced that it has entered into a strategic collaboration agreement with Bristol-Myers Squibb Company to discover, develop and commercialize novel macrocyclic compounds directed against targets of interest to Bristol-Myers Squibb.

8 Dec 2009

Ghrelin News and Research

Further Reading

Ipsen's first-quarter 2010 drug sales up 6.2%

Dietary protein for overall health

Laughter is truly the best medicine says new research

Laughter increases production of antibodies and activates body's protective cells

Eating protein-rich eggs for breakfast reduces hunger, decreases calorie consumption throughout the day

Hormone ghrelin may improve appetite in gastric cancer patients

Tranzyme Pharma's ulimorelin Phase 2 trial data selected for presentation at DDW 2010

Ipsen grants Rhythm exclusive global license for melanocortin and ghrelin programs

Study shows ghrelin prevents acute liver damage, reduces oxidative stress and inflammation

10th Annual Spring Meeting of ESC on Cardiovascular Nursing and Allied Professionals

USAN approves generic name "ulimorelin" for Tranzyme Pharma's TZP-101

Phase 1 clinical trial of SIRT1 inhibitor for the treatment of Huntington’s Disease commenced

Hunger hormone can intensify high-fat food consumption

Hormone ghrelin influences the consumption of alcohol, study shows

AEterna Zentaris terminates its agreement on cetrorelix with sanofi-aventis U.S.

Tranzyme Pharma and Bristol-Myers Squibb sign collaboration agreement

Phase 3 results for European efficacy trial Z-036 in BPH with cetrorelix pamoate reported

Æterna Zentaris reports Phase 3 results of its cetrorelix pamoate Z-036 trial for BPH

Study reveals that ghrelin can increase resistance to Parkinson's disease

Aeterna Zentaris reports consolidated revenues of $8.6 million for third quarter 2009

Achieving and maintaining ISO 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Examining how pain could play a direct protective role in the gut

Latest News